{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T22:44:45Z","timestamp":1759099485238},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,8,8]],"date-time":"2007-08-08T00:00:00Z","timestamp":1186531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,8,8]],"date-time":"2007-08-08T00:00:00Z","timestamp":1186531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Compr Ther"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s12019-007-0014-0","type":"journal-article","created":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T17:08:16Z","timestamp":1186506496000},"page":"150-161","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pulmonary Hypertension: Evaluation and Management"],"prefix":"10.1007","volume":"33","author":[{"given":"Gustavo A.","family":"Heresi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raed A.","family":"Dweik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,8]]},"reference":[{"key":"14_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425\u201336.","journal-title":"N Engl J Med"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"40S","DOI":"10.1016\/j.jacc.2004.02.032","volume":"43","author":"RJ Barst","year":"2004","unstructured":"Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S\u20137S.","journal-title":"J Am Coll Cardiol"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2006.11.012","volume":"28","author":"DB Taichman","year":"2007","unstructured":"Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007;28:1\u201322, vii.","journal-title":"Clin Chest Med"},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","volume":"107","author":"S Rich","year":"1987","unstructured":"Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216\u201323.","journal-title":"Ann Intern Med"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","volume":"173","author":"M Humbert","year":"2006","unstructured":"Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023\u201330.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/79226","volume":"26","author":"KB Lane","year":"2000","unstructured":"Lane KB, Machado RD, Pauciulo MW, Thompson JR, Phillips JA, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81\u20134.","journal-title":"Nat Genet"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ccm.2006.11.007","volume":"28","author":"ED Austin","year":"2007","unstructured":"Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 2007;28:43\u201357, vii\u2013viii.","journal-title":"Clin Chest Med"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1378\/chest.100.5.1268","volume":"100","author":"R Speich","year":"1991","unstructured":"Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268\u201371.","journal-title":"Chest"},{"key":"14_CR9","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1378\/chest.130.6.1657","volume":"130","author":"KM Chin","year":"2006","unstructured":"Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006;130:1657\u201363.","journal-title":"Chest"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1183\/09031936.03.00038903","volume":"22","author":"P Dorfmuller","year":"2003","unstructured":"Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358\u201363.","journal-title":"Eur Respir J"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra035488","volume":"351","author":"HW Farber","year":"2004","unstructured":"Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655\u201365.","journal-title":"N Engl J Med"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199207093270202","volume":"327","author":"BW Christman","year":"1992","unstructured":"Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70\u20135.","journal-title":"N Engl J Med"},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","volume":"159","author":"RM Tuder","year":"1999","unstructured":"Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et\u00a0al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","volume":"114","author":"DJ Stewart","year":"1991","unstructured":"Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464\u20139.","journal-title":"Ann Intern Med"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","volume":"120","author":"C Rubens","year":"2001","unstructured":"Rubens C, Ewert R, Halank M, Wensel R, Orzechowski H-D, Schultheisset H-P, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562\u20139.","journal-title":"Chest"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A Giaid","year":"1993","unstructured":"Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732\u20139.","journal-title":"N Engl J Med"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/ajrccm.158.3.9802066","volume":"158","author":"FT Kaneko","year":"1998","unstructured":"Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998;158:917\u201323.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s004080000064","volume":"179","author":"M Ozkan","year":"2001","unstructured":"Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001;179:233\u201343.","journal-title":"Lung"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJM199507273330403","volume":"333","author":"A Giaid","year":"1995","unstructured":"Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214\u201321.","journal-title":"N Engl J Med"},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1096\/fj.04-2317fje","volume":"18","author":"W Xu","year":"2004","unstructured":"Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, et\u00a0al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. Faseb J 2004;18:1746\u20138.","journal-title":"Faseb J"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","volume":"43","author":"M Humbert","year":"2004","unstructured":"Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S\u201324S.","journal-title":"J Am Coll Cardiol"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ccm.2006.11.001","volume":"28","author":"TK Trow","year":"2007","unstructured":"Trow TK, McArdle JR. Diagnosis of pulmonary arterial hypertension. Clin Chest Med 2007;28:59\u201373, viii.","journal-title":"Clin Chest Med"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1378\/chest.122.2.524","volume":"122","author":"GS Ahearn","year":"2002","unstructured":"Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002;122:524\u20137.","journal-title":"Chest"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1378\/chest.126.1_suppl.14S","volume":"126","author":"M McGoon","year":"2004","unstructured":"McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S\u201334S.","journal-title":"Chest"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1378\/chest.06-1378","volume":"131","author":"OA Minai","year":"2007","unstructured":"Minai OA, Pandya CM, Golish JA, Avecillas JF, McCarthy K, Marlow S, et al. Predictors of nocturnal oxygen desaturation in pulmonary arterial hypertension. Chest 2007;131:109\u201317.","journal-title":"Chest"},{"key":"14_CR26","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","volume":"126","author":"DB Badesch","year":"2004","unstructured":"Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S\u201362S.","journal-title":"Chest"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","volume":"111","author":"O Sitbon","year":"2005","unstructured":"Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et\u00a0al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105\u201311.","journal-title":"Circulation"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","volume":"25","author":"N Galie","year":"2004","unstructured":"Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243\u201378.","journal-title":"Eur Heart J"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"78S","DOI":"10.1378\/chest.126.1_suppl.78S","volume":"126","author":"VV McLaughlin","year":"2004","unstructured":"McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S\u201392S.","journal-title":"Chest"},{"key":"14_CR30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","volume":"102","author":"N Nagaya","year":"2000","unstructured":"Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865\u201370.","journal-title":"Circulation"},{"key":"14_CR31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D\u2019Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343\u20139.","journal-title":"Ann Intern Med"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et\u00a0al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296\u2013302.","journal-title":"N Engl J Med"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1183\/09031936.05.00054804","volume":"25","author":"VV McLaughlin","year":"2005","unstructured":"McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Gali\u00e8 N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244\u20139.","journal-title":"Eur Respir J"},{"key":"14_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1161\/CIRCULATIONAHA.104.503540","volume":"114","author":"VV McLaughlin","year":"2006","unstructured":"McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417\u201331.","journal-title":"Circulation"},{"key":"14_CR35","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1183\/09031936.05.00075305","volume":"26","author":"MM Hoeper","year":"2005","unstructured":"Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858\u201363.","journal-title":"Eur Respir J"},{"key":"14_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccm.2006.11.011","volume":"28","author":"D O\u2019Callaghan","year":"2007","unstructured":"O\u2019Callaghan D, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007;28:169\u201385, ix.","journal-title":"Clin Chest Med"},{"key":"14_CR37","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et\u00a0al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148\u201357.","journal-title":"N Engl J Med"},{"key":"14_CR38","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","volume":"48","author":"R Voswinckel","year":"2006","unstructured":"Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48:1672\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"14_CR39","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","volume":"47","author":"RJ Barst","year":"2006","unstructured":"Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment of pulmonary arterial hypertension with the selective endothelin\u2014a receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"14_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","volume":"46","author":"N Galie","year":"2005","unstructured":"Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"14_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccm.2006.12.002","volume":"28","author":"JR Klinger","year":"2007","unstructured":"Klinger JR. The nitric oxide\/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007;28:143\u2013167, ix.","journal-title":"Clin Chest Me"}],"container-title":["Comprehensive Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12019-007-0014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12019-007-0014-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12019-007-0014-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12019-007-0014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:48:22Z","timestamp":1659091702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12019-007-0014-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,8]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1007\/s12019-007-0014-0","relation":{},"ISSN":["0098-8243","1559-1190"],"issn-type":[{"value":"0098-8243","type":"print"},{"value":"1559-1190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,8]]},"assertion":[{"value":"12 June 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}